Pfizer reported flat revenue (up 7% excluding covid products) and flat earnings in the third quarter. Management raised the midpoints of its 2026 guidance for sales (to $63 billion from $61.5 billion) and adjusted diluted earnings per share (to $3.00 from $2.90). Shares fell 1% intraday on Nov. 3.
Pfizer's portfolio contains several blockbusters, including differentiated cardiovascular drug Vyndamax and oncology drug Padcev.
Aggressive cost-cutting in research and development could hurt Pfizer's long-term prospects, given the importance of continued investment in innovation.
|
Metric
|
PFE
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.17 | 111.70 | 13.93 |
Price/Book Value | 1.97 | 8.26 | 4.13 |
Price/Sales | 2.78 | 5.52 | 2.32 |
Price/Cash Flow | 11.94 | 16.81 | 10.29 |
|
Metric
|
PFE
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 1.00 | 0.78 | 0.55 |
Current Ratio | 1.42 | 1.35 | 0.86 |
Interest Coverage | 2.39 | 3.33 | 8.21 |
|
Metric
|
PFE
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | 8.49% | 2.53% | 11.16% |
Return on Equity (Normalized) | 19.73% | 7.02% | 40.86% |
Return on Invested Capital (Normalized) | 12.71% | 4.79% | 21.39% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|N?mjcfL | LOCK|d^! | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|Q&@$#M | LOCK|#%^ | $665B | |||
| AbbVie Inc
ABBV
| LOCK|&@>VGY | LOCK|>$ | $521B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|QbLprLnR | LOCK|&K | $386B | |||
| Merck & Co Inc
MRK
| LOCK|$Jt^Gv% | LOCK|KzQ | $371B | |||
| Novartis AG ADR
NVS
| LOCK|V!pBXlfs | LOCK|&N# | $309B | |||
| AstraZeneca PLC
AZN
| LOCK|!$vqB$$ | LOCK|SH> | $292B | |||
| Amgen Inc
AMGN
| LOCK|yr&^ycHz | LOCK|Jw$ | $259B | |||
| Gilead Sciences Inc
GILD
| LOCK|Z@@>Kz? | LOCK|<^ | $216B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Y^mG#p | LOCK|gK | $189B |
United States